Skip to main content
. 2021 Apr 19;65(5):e02420-20. doi: 10.1128/AAC.02420-20

FIG 3.

FIG 3

EC/11770 is active against M. abscessus in vivo. Lung CFU (A) and spleen CFU (B) from NOD SCID mice 1 day after intranasal infection with Mab (drug-free day 1) and following daily oral administration of drug-free vehicle, clarithromycin (CLR), or EC/11770 for 10 days (day 11). Data represent the mean plus standard deviation of six mice per treatment group. Statistical significance of the results was analyzed by one-way analysis of variance (ANOVA) multicomparison and Tukey’s posttest (*, P < 0.05; **, P < 0.01; ***, P < 0.001).